According to ADMA Biologics 's latest financial reports and stock price the company's current number of shares outstanding is 225,276,980. At the end of 2023 the company had 225,276,980 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Year | Shares Outstanding | Change |
---|---|---|
2023 | 0.22 B | 11.07% |
2022 | 0.20 B | 12.18% |
2021 | 0.18 B | 87.14% |
2020 | 96.62 M | 62.88% |
2019 | 59.31 M | 27.98% |
2018 | 46.35 M | 79.72% |
2017 | 25.79 M | 100.13% |
2016 | 12.88 M | 20.35% |
2015 | 10.7 M | 15.24% |
2014 | 9.29 M | 58.27% |
2013 | 5.87 M | -0.68% |
2012 | 5.91 M | 136.44% |
2011 | 2.5 M | 0% |
2010 | 2.5 M | 0% |
2009 | 2.5 M |
Company | Shares Outstanding | differencediff. | Country |
---|---|---|---|
Repligen
RGEN | 55,815,666 | -75.22% | ๐บ๐ธ USA |
Novavax NVAX | 103,429,000 | -54.09% | ๐บ๐ธ USA |
Cel-Sci
CVM | 48,470,600 | -78.48% | ๐บ๐ธ USA |